Janney Montgomery Scott LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,401 shares of the life sciences company’s stock after buying an additional 1,407 shares during the period. Janney Montgomery Scott LLC’s holdings in Illumina were worth $9,445,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Massmutual Trust Co. FSB ADV increased its holdings in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the period. Financial Advocates Investment Management increased its holdings in shares of Illumina by 1,430.0% in the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 572 shares during the period. Proficio Capital Partners LLC increased its holdings in shares of Illumina by 61.7% in the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. C J Advisory Inc acquired a new position in shares of Illumina in the first quarter valued at approximately $29,000. Finally, Lake Point Wealth Management acquired a new position in shares of Illumina in the fourth quarter valued at approximately $30,000. 90.56% of the stock is currently owned by institutional investors.
Shares of ILMN stock opened at $325.52 on Friday. Illumina, Inc. has a 1-year low of $236.71 and a 1-year high of $372.61. The firm has a market cap of $47.85 billion, a P/E ratio of 56.91, a price-to-earnings-growth ratio of 2.17 and a beta of 1.15. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27.
ILMN has been the topic of a number of recent research reports. Morgan Stanley dropped their target price on Illumina from $320.00 to $288.00 and set an “equal weight” rating on the stock in a report on Monday, January 7th. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $347.00 target price on the stock in a report on Friday, January 11th. Deutsche Bank lowered Illumina from a “buy” rating to a “hold” rating and set a $296.53 target price on the stock. in a report on Friday, January 25th. BidaskClub lowered Illumina from a “hold” rating to a “sell” rating in a report on Tuesday, January 29th. Finally, Leerink Swann raised Illumina to an “outperform” rating and dropped their price objective for the stock from $380.00 to $365.00 in a report on Wednesday, January 30th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $353.58.
In other Illumina news, Director Robert S. Epstein sold 5,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $310.44, for a total transaction of $1,552,200.00. Following the sale, the director now directly owns 8,256 shares in the company, valued at $2,562,992.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $321.96, for a total value of $1,062,468.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,826 shares of company stock worth $12,022,575. 0.38% of the stock is owned by company insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: Float
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.